ATTENUKINE Trademark

Trademark Overview

On Thursday, January 6, 2022, a trademark application was filed for ATTENUKINE with the United States Patent and Trademark Office. The USPTO has given the ATTENUKINE trademark a serial number of 97205484. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, December 18, 2024. This trademark is owned by Teva Pharmaceutical Industries Ltd.. The ATTENUKINE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer and autoimmune diseases

General Information

Serial Number97205484
Word MarkATTENUKINE
Filing DateThursday, January 6, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, December 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 23, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 10, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTeva Pharmaceutical Industries Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTel Aviv 6944020
IL
Party NameTeva Pharmaceutical Industries Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTel Aviv 6944020
IL

Trademark Events

Event DateEvent Description
Thursday, October 13, 2022ASSIGNED TO EXAMINER
Monday, January 10, 2022NEW APPLICATION ENTERED
Monday, January 10, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 13, 2022NON-FINAL ACTION WRITTEN
Thursday, October 13, 2022NON-FINAL ACTION E-MAILED
Thursday, October 13, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 15, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 1 FILED
Wednesday, January 10, 2024SOU EXTENSION 1 GRANTED
Wednesday, July 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 17, 2024SOU EXTENSION 2 GRANTED
Wednesday, July 17, 2024SOU EXTENSION 2 FILED
Wednesday, December 18, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, December 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 18, 2024SOU EXTENSION 3 GRANTED
Wednesday, December 18, 2024SOU EXTENSION 3 FILED
Wednesday, July 17, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

attenukine autoimmune diseases cancer treatment preparations pharmaceutical